Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Edaravone injection for treating acute cerebral thrombus and its prepn

A technology of Edarafon and injections, which is applied in the fields of emulsion delivery, liquid delivery, cardiovascular system diseases, etc., can solve the problem of low incidence, achieve stable quality, controllable quality standards, and safe treatment of acute cerebral infarction Effect

Inactive Publication Date: 2003-09-10
HONGYI SCI & TECH CO LTD NANCHANG
View PDF0 Cites 35 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Patients with cerebral infarction were given 10mg / time, 30mg / time, 45mg / time respectively, twice / day for 14 days, and the side effects were 4 / 120 cases and 3 / 113 cases in the low, medium and high dose groups respectively cases, 7 / 112 cases, mainly liver dysfunction, but its incidence rate was lower than that of the placebo group in clinical trials of other cerebral infarction therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0055] Eda Lafon 3.0g

[0056] Sodium bisulfite 2.0g

[0057] L-cysteine ​​hydrochloride 1.0g

example 3

[0059] Eda Lafon 6.0g

[0060] Sodium bisulfite 4.0g

[0061] L-cysteine ​​hydrochloride 2.0g

[0062] Add water for injection to 1000ml, pack into 200 sticks, 5ml / stick

[0063] The preparation technology of Yidalafen injection in above-mentioned example

[0064] Take Edalabon, sodium bisulfite, L-cysteine ​​hydrochloride, add water for injection, stir, decarbonize, coarse filter, fill, seal, and sterilize at high temperature.

[0065] 4. Example 4

[0066] Edarafon 0.6g

[0067] Sodium chloride 9g

[0068] Sodium bisulfite 0.4g

[0069] L-cysteine ​​hydrochloride 0.2g

[0070] Add water for injection to 1000ml, pack into 20 bottles, 50ml / bottle five, example 5

[0071] Edarafon 0.3g

[0072] Sodium chloride 9g

[0073] Sodium bisulfite 0.4g

[0074] L-cysteine ​​hydrochloride 0.2g

[0075] Add water for injection to 1000ml, pack into 10 bottles, 100ml / bottle 6. Example 6

[0076] Edarafon 0.12g

[0077] Sodiu...

example 7

[0081]Edarafon 0.06g

[0082] Sodium chloride 9g

[0083] Sodium bisulfite 0.4g

[0084] L-cysteine ​​hydrochloride 0.2g

[0085] Add water for injection to 1000ml, divide into 2 bottles, 500ml / bottle 8. Example 8

[0086] Edarafon 0.6g

[0087] Glucose 50g

[0088] Sodium bisulfite 0.4g

[0089] L-cysteine ​​hydrochloride 0.2g

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The Edaravone injection of the present invention is a kind of free radical eliminating medicine to treat acute cerebral infarction. It is injection prepared with Edaravone, additive and solvent and in the form of sterilized solution, emulsion or suspension. It may be small capacity sterilized injection, great capacity sterilized injection, bacteria-free powder preparation for injection, freeze dried powder preparation for injection, sterilized suspension injection or sterilized emulsion injection.

Description

technical field [0001] The invention relates to a drug injection for treating acute cerebral infarction and a preparation process thereof, specifically, a chemical name of 3-methyl-1-phenyl-2-pyrazolin-5-one with a structural formula of The molecular formula and molecular weight are C 10 h 10 N 2 O 174.20 Edralafen as sterile solution, emulsion or suspension for injection into the body, and sterile powder or concentrated solution for solution or suspension immediately before use. technical background [0002] Cerebrovascular diseases, malignant tumors and cardiovascular diseases are the three most common causes of death in humans at present. Stroke has become one of the major diseases that seriously threaten human life and health due to its high morbidity, high mortality and high disability rate. one. In my country, there are 120-180 / 100,000 new stroke cases every year, 250 / 100,000 annual prevalence, 122.4 / 100,000 mortality rate, 6 million stroke survivors nationwide, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K31/4152A61P9/10
Inventor 刘孝乐刘智钱进许军彭红李平朱丹
Owner HONGYI SCI & TECH CO LTD NANCHANG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com